We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.8%.
The Zacks Consensus Estimate for revenues is pegged at $3.8 billion, suggesting a 1.6% rise from the year-ago quarter’s actual. Growth in the top line is expected to have been led by the rising demand for IQVIA’s technology-enabled analytics solutions and the development of novel respiratory vaccines.
Our estimate for revenues from the Technology and Analytics segment is pegged at $1.5 billion, indicating a 1.6% gain on a year-over-year basis. Revenue growth is likely to have been driven by the rising demand for sophisticated technology-enabled analytics solutions. IQV’s technology provides real-time data sharing, eliminating unwanted file processing and enhancing the speed of data updates.
The Research and Development segment’s revenues are expected to be $2.1 billion, implying a 1.7% rise from the year-ago reported figure.The top 10 pharmaceutical companies chose IQVIA to support the novel respiratory vaccine development, which could lead to a breakthrough as the vaccine targets several respiratory viruses simultaneously. Such a feat is anticipated to have benefited this segment’s revenues.Our estimate for Contract sales and Medical solutions’ revenues is pegged at $177 million, implying marginal growth from the year-ago actual.
The consensus estimate for earnings per share is pegged at $2.6, indicating 6.2% year-over-year growth. The company is expected to have benefited from strong margins.
Our estimate for the second quarter’s adjusted EBITDA is pegged at $874.6 million, suggesting 1.2% year-over-year growth.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV currently has an Earnings ESP of 0.00% and a Zacks Rank of 3.
Stocks to Consider
Here are a few stocks from the broader Business Services sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
S&P Global (SPGI - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter revenues is pegged at $3.4 billion, suggesting growth of 8.6% from the year-ago quarter. For earnings, the consensus mark is pegged at $3.5 per share, indicating a 12.2% year-over-year rise. SPGI beat the consensus estimate in the past four quarters. It has an earnings surprise of 3.4%, on average.
SPGI currently has an Earnings ESP of +6.78% and a Zacks Rank of 2. It is scheduled to declare its second-quarter 2024 results on Jul 30.
Trane Technologies (TT - Free Report) : The Zacks Consensus Estimate for second-quarter revenues is pegged at $5.1 billion, indicating an increase of 8.7% from the year-ago quarter’s actual. For earnings, the consensus mark is pegged at $3.1 per share, indicating a 14.9% increase from the year-ago quarter’s actual. TT beat the consensus estimate in the past four quarters. It has an earnings surprise of 7.5%, on average.
TT currently has an Earnings ESP of +0.95% and a Zacks Rank of 2. It is scheduled to declare its second-quarter 2024 results on Jul 31.
Image: Bigstock
IQVIA (IQV) to Report Q2 Earnings: What's in the Offing?
IQVIA Holdings, Inc. (IQV - Free Report) is scheduled to release its second-quarter 2024 results on Jul 22, before market open.
IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.8%.
IQVIA Holdings Inc. Price and EPS Surprise
IQVIA Holdings Inc. price-eps-surprise | IQVIA Holdings Inc. Quote
Q2 Expectations
The Zacks Consensus Estimate for revenues is pegged at $3.8 billion, suggesting a 1.6% rise from the year-ago quarter’s actual. Growth in the top line is expected to have been led by the rising demand for IQVIA’s technology-enabled analytics solutions and the development of novel respiratory vaccines.
Our estimate for revenues from the Technology and Analytics segment is pegged at $1.5 billion, indicating a 1.6% gain on a year-over-year basis. Revenue growth is likely to have been driven by the rising demand for sophisticated technology-enabled analytics solutions. IQV’s technology provides real-time data sharing, eliminating unwanted file processing and enhancing the speed of data updates.
The Research and Development segment’s revenues are expected to be $2.1 billion, implying a 1.7% rise from the year-ago reported figure.The top 10 pharmaceutical companies chose IQVIA to support the novel respiratory vaccine development, which could lead to a breakthrough as the vaccine targets several respiratory viruses simultaneously. Such a feat is anticipated to have benefited this segment’s revenues.Our estimate for Contract sales and Medical solutions’ revenues is pegged at $177 million, implying marginal growth from the year-ago actual.
The consensus estimate for earnings per share is pegged at $2.6, indicating 6.2% year-over-year growth. The company is expected to have benefited from strong margins.
Our estimate for the second quarter’s adjusted EBITDA is pegged at $874.6 million, suggesting 1.2% year-over-year growth.
What Our Model Says
Our proven model does not conclusively predict an earnings beat for IQVIA this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter.
IQV currently has an Earnings ESP of 0.00% and a Zacks Rank of 3.
Stocks to Consider
Here are a few stocks from the broader Business Services sector, which, according to our model, have the right combination of elements to beat on earnings this time around.
S&P Global (SPGI - Free Report) : The Zacks Consensus Estimate for the company’s second-quarter revenues is pegged at $3.4 billion, suggesting growth of 8.6% from the year-ago quarter. For earnings, the consensus mark is pegged at $3.5 per share, indicating a 12.2% year-over-year rise. SPGI beat the consensus estimate in the past four quarters. It has an earnings surprise of 3.4%, on average.
SPGI currently has an Earnings ESP of +6.78% and a Zacks Rank of 2. It is scheduled to declare its second-quarter 2024 results on Jul 30.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Trane Technologies (TT - Free Report) : The Zacks Consensus Estimate for second-quarter revenues is pegged at $5.1 billion, indicating an increase of 8.7% from the year-ago quarter’s actual. For earnings, the consensus mark is pegged at $3.1 per share, indicating a 14.9% increase from the year-ago quarter’s actual. TT beat the consensus estimate in the past four quarters. It has an earnings surprise of 7.5%, on average.
TT currently has an Earnings ESP of +0.95% and a Zacks Rank of 2. It is scheduled to declare its second-quarter 2024 results on Jul 31.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.